Protecting nerves from damage caused by chemotherapy
Official title: Neuroprotection for chemotherapy induced peripheral neuropathy
Funded at University of North Carolina Charlotte · NIH-10876054 · Data updated 2026-11-12
This study is looking at how a drug called Fluocinolone acetonide might help prevent painful nerve damage from chemotherapy, especially for those receiving a common treatment called Paclitaxel, so patients can feel better while getting their cancer care.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Carolina Charlotte NIH-funded |
| Lab location | 1 site (Charlotte, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2027 |
| Funding year | 2024 |
| Award (this year) | $462,000 |
| NIH project number | 1R15CA290570-01 |
| Project ID | NIH-10876054 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients undergoing chemotherapy for non-small cell lung cancer who are experiencing or at risk of developing peripheral neuropathy.
✕Less likely to help
Patients who are not receiving chemotherapy or those with pre-existing neuropathy unrelated to chemotherapy may not benefit from this research.
What this research studies
This research investigates how to prevent nerve damage caused by chemotherapy, specifically focusing on a common drug called Paclitaxel. Patients undergoing chemotherapy often experience painful side effects known as chemotherapy induced peripheral neuropathy (CIPN), which can lead to reduced treatment effectiveness. The study aims to identify a neuroprotective drug, Fluocinolone acetonide, that may help mitigate these painful symptoms. By using advanced imaging techniques, researchers will explore how this drug affects nerve cell function and health.
Why it matters
Potential benefit: If successful, this research could significantly improve the quality of life for cancer patients by reducing painful side effects of chemotherapy.
How similar studies have gone: While the approach of using Fluocinolone acetonide for this purpose is innovative, similar studies have shown promise in exploring neuroprotective strategies for chemotherapy-induced side effects.
Where this research is happening
-
University of North Carolina Charlotte
Charlotte, United States Active
Researchers
- Principal investigator: Yang, in Hong — University of North Carolina Charlotte
- Study coordinator: Yang, in Hong
Related research
Other NIH-funded projects on the same topics.
-
Non-invasive, microscopic biomarkers to detect CIPN in chemotherapy patients
This grant aims to develop a non-invasive imaging method to measure nerve changes in patients undergoing chemotherapy to better understand and monitor chemotherapy-induced peripheral neuropathy (CIPN).
-
Longitudinal study of how body-sense relates to chemotherapy nerve damage
This study follows people with breast or gastrointestinal cancer and healthy controls to see if brain processing of body sensations contributes to chemotherapy-induced nerve damage.
-
A new screen for chemotherapy-related nerve problems in young children
A clinician-scientist at Yale is developing a child-friendly survey to quickly screen for nerve-related side effects from cancer treatment in kids from birth to age 5.
-
How the immune system’s CD4+ T cells in women might prevent chemotherapy-related nerve pain
A study in mice explores whether female immune cells in nerve tissue can lessen pain from chemotherapy, with potential implications for preventing CIPN in women.
-
Axonal transport and chemotherapy-related nerve pain
This grant studies why certain cancer patients develop painful nerve damage from chemotherapy and explores ways to prevent or treat it.
-
Remote monitoring and nurse follow-up to manage chemotherapy-induced peripheral neuropathy
A program uses symptom reporting tools with nurse follow-up to reduce and better manage chemotherapy-induced neuropathy for cancer survivors, during and after treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.